Summary:
Researchers in the Department of Ophthalmology at UCLA have developed an intravitreal injection device for safer and more precise injections.
Background:
Intravitreal injections are vital for treating sight-threatening retinal conditions like age-related macular degeneration and diabetic macular edema. These conditions rely heavily on accurate and consistent drug delivery into the vitreous humor of the eye. However, current intravitreal injection methods present several challenges. The procedure can be uncomfortable for the patient and repetitive injections heighten the risk of complications. Innovative intravitreal injection devices with features such as improved precision, safety mechanisms, and extended drug delivery capabilities could significantly enhance patient comfort, reduce the complication or risks, and improve treatment outcomes.
Innovation:
UCLA researchers have developed a concept for a novel ophthalmological injection device designed to improve the safety, precision, and ease of eye injections. Made from FDA-approved, recyclable plastic, the device is cost-effective to manufacture and compact enough to fit into standard intravitreal injection packaging. It features a transparent base with markings for standardized injection sites (3.5mm and 4mm from the limbus), a round circumference for better anatomical placement, and a thin yet sturdy structure that prevents interference with needle entry while ensuring a safe stop for the needle. The base includes small pyramidal points to minimize slipping on the ocular surface without causing abrasions. The handle is angled steeply enough to avoid compressing the eyelid or facial features but not so steep as to obstruct visualization or syringe access. This innovative, environmentally friendly device is designed to enhance injection procedures for medical professionals while addressing the growing demand for intravitreal injections.
Potential Applications:
• Precision drug delivery in ophthalmology, including, but not limited to, intravitreal injections, subconjunctival injections, and periocular injections
• Minimally Invasive Treatments for Glaucoma or Corneal Treatments
• Pre-Surgical Preparation for delivery of anesthetics or antibiotics prior to eye surgery
Advantages:
• Safer injections
• Cost effective
• Easy to package
• Recyclable
• Small and compact, easy to package in any intravitreal package
• Biocompatible materials and recyclable
State of Development:
The inventors have externally presented the concept in January of 2024 and researchers are seeking support for development and prototyping of the device.
Reference:
UCLA Case No. 2024-136